Trial · NCT03217747
Results by group98
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 98
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm A Exp Avelumab Starting From C1D15 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm A Exp Avelumab Starting From C3D1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm B Exp Avelumab Starting From C1D15 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm B Exp Avelumab Starting From C3D1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm C Escalation Avelumab Starting From C1D1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm C Exp Avelumab Starting From C1D15 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm C Exp Avelumab Starting From C3D1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm D Esc Schedule-1 Dose Level 1; XRT: Starting C1D2 to C1D11 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm D Esc Schedule-2 Dose Level 1; XRT: Starting Days -14 to -1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm D Esc Schedule-3 Dose Level 1; XRT: Starting C1D1 to C1D3 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm E Esc Schedule-1 Dose Level 1; XRT: Starting C1D2 to C1D11 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm E Esc Schedule-2 Dose Level 1; XRT: Starting Days -14 to -1 | 0 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm F Esc Schedule-1 Dose Level 1; Avelumab Starting From C1D1, XRT: Starting C1D2 to C1D11 | 2 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) (All Will be Graded According to CTCAEv4.03 Criteria) | Arm F Esc Schedule-2 Dose Level 1; Avelumab Starting From C1D15, XRT: Starting Days -14 to -1 | 0 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm A Exp Avelumab Starting From C1D15 | 0 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm A Exp Avelumab Starting From C3D1 | 1 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm B Exp Avelumab Starting From C1D15 | 0 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm B Exp Avelumab Starting From C3D1 | 0 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm C Escalation Avelumab Starting From C1D1 | 0 | Participants | ||
| Objective Response Rate Per RECIST v1.1 | Arm C Exp Avelumab Starting From C1D15 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03217747/results